Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PDGFRβ was an independent predictor of poor survival in the overall Norwegian cohort and an independent predictor of increased survival in the ADC (adenocarcinoma) subgroup of the Swedish cohort.
|
31308421 |
2019 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We analyzed positron emission tomography-computed tomography (PET-CT) in patients with stage III non-small-cell lung cancer (NSCLC) undergoing concurrent chemoradiotherapy (CRT) to examine the prognostic value of PET-CT parameters according to histologic subtypes (squamous cell carcinoma [SqCC] and adenocarcinoma [ADC]).
|
30266585 |
2019 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We analyzed immune markers in formalin-fixed, paraffin-embedded tumor tissues resected from 112 patients with stage II/III NSCLC, including 61 non-NCT (adenocarcinoma [ADC] = 33; squamous cell carcinoma [SCC] = 28) and 51 NCT (ADC = 31; SCC = 20).
|
29871672 |
2018 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This study describes pooled and country-specific anal cancer incidence trends by sex, age (all ages, <60 and 60+ years) and histological subtype (all subtypes, squamous cell carcinoma [SCC] and adenocarcinoma [ADC]).
|
30339668 |
2018 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine whether distinct tissue immune microenvironments differentially affect clinical outcome in non-small cell lung cancer (NSCLC), an extended analysis of PD-L1 and tumor-infiltrating lymphocytes (TIL) was performed.<b>Experimental Design:</b> Samples from resected adenocarcinoma (ADC 42), squamous cell carcinoma (SCC 58), and 26 advanced diseases (13 ADC and 13 SCC) treated with nivolumab were analyzed.
|
29074606 |
2018 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PTEN expression was significantly correlated with gender, smoking history, histology (adenocarcinoma [ADC] vs. squamous cell carcinoma), tumor node metastasis stage (I-II vs. III-IV), N status (N0 vs. N1-N3), and distant metastasis (M0 vs. M1).
|
28263037 |
2017 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Matching one patient with LTI for 2 patients without LTI who had completed treatment between 1995 and 2012 were conducted by using treatment modalities (radiation therapy [RT] alone vs. concurrent chemoradiation therapy [CCRT]) and tumor histology (squamous cell carcinoma [SCC] vs. adenocarcinoma [ADC]).
|
29027397 |
2017 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Primary endpoint: EGFR mutation frequency in aNSCLC patients (adenocarcinoma [ADC]/non-ADC), as per local practices.
|
29110846 |
2017 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Significant increase of PELP1 transcript/protein level was found in all patients, regardless of gender (males: P=0.0003/P=0.000003; females: P=0.0005/P=0.02), age (≤ 60 patients: P=0.042/P=0.016; >60 patients: P=0.00001/P=0.00001) or histopathological type of tumor (adenocarcinoma [ADC]: P=0.004/P=0.0006; squamous cell carcinoma [SSC]: P=0.0009/P=0.0008).
|
26211588 |
2015 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
46 bronchoscopic biopsy samples (27 squamous cell carcinomas /SCC/ and 19 adenocarcinomas /ADC/) together with their corresponding surgical biopsies were studied.
|
25194563 |
2015 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In conclusion, ITIH5 may be a novel putative tumor suppressor gene in NSCLC with a potential molecular significance in the squamoid ADC subtype and further clinical impact for risk stratification of adenocarcinoma patients.
|
26252352 |
2015 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
hMLH1 and hMSH2 mRNA expression was previously evaluated by qPCR for 29 NSCLC patients (13 with squamous cell carcinoma [SQC] and 16 with adenocarcinoma [ADC]) and MMR mRNA levels were converted into clinically distinct phenotypic entities.
|
22865300 |
2013 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
One meta-analysis generated a 'mutMap' to visually represent mutation coincidence by ethnicity (Western/Asian) and histology (adenocarcinoma [ADC] or squamous cell carcinoma).
|
23723294 |
2013 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, we included 379 patients who underwent surgical resection (179 diagnosed as having adenocarcinoma [ADC]; 150, squamous cell carcinoma [SCC]; 41, sarcomatoid carcinoma and 9, large cell carcinoma).
|
23266446 |
2013 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, p62 and VPRBP were associated with poor prognosis in lung ADC (adenocarcinoma) (p62, P=0.019; VPRBP, P=0.005).
|
22963397 |
2013 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We analyzed 56 surgically resected lung tumors classified as LCC on the basis of pure morphologic grounds, using a panel of immunophenotypic markers (adenocarcinoma [ADC]-specific, thyroid transcription factor-1, cytokeratin 7, and napsin A; squamous cell carcinoma [SQCC]-specific, p63, cytokeratin 5, desmocollin 3, and Δnp63) and the quantitative analysis of microRNA-205 (microRNA sample score [mRSS]).
|
22031317 |
2011 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The NNK-ADC expression signature also separated both mouse and human adenocarcinomas from adjacent normal lung tissues based on publicly available microarray datasets.
|
20686609 |
2010 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
K-RAS was mutated in 12.2% of NSCLC tumours, the majority of the mutations being found in ADC (adenocarcinoma, 27.0%).
|
18957720 |
2008 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A cytogenetic study of pleural effusions (PE) containing metastatic or invasive tumor cells from 11 patients with non-small cell lung cancer (NSCLC) (3 squamous cell carcinomas [SQC] and 8 adenocarcinomas [ADC] including 1 giant cell variant) was performed to identify non-random chromosome abnormalities.
|
7512370 |
1993 |